Clinical Trials Logo

Clinical High Risk for Psychosis clinical trials

View clinical trials related to Clinical High Risk for Psychosis.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT02557945 Terminated - Clinical trials for Clinical High Risk for Psychosis

Gabapentin in Patients at Clinical Risk for Psychosis

Start date: August 1, 2015
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to test the effects of the drug gabapentin on brain function thought to be important in the development of schizophrenia. Researchers think that treating a brain region with gabapentin (the hippocampus) may reduce the risk for developing schizophrenia.

NCT ID: NCT02047539 Terminated - Clinical trials for Clinical High Risk for Psychosis

Randomized Controlled Trial of Aspirin vs Placebo in the Treatment of Pre-psychosis

Start date: January 2015
Phase: Early Phase 1
Study type: Interventional

The primary objective of this study is to determine whether aspirin is effective in alleviating symptoms of the clinical high risk (CHR) syndrome for psychosis. The investigators further aim to determine whether it may delay or prevent the onset of psychosis in those currently experiencing CHR symptoms. As secondary measures the investigators aim to collect laboratory studies of inflammation markers and genetic samples to determine whether certain genetic profiles correlate with risk for psychosis, or response to aspirin treatment.